Continuing Assessment of Patients Treated With ranibizUmab for REtinal Vein Occlusion (CAPTURE)

Sponsor
Johns Hopkins University (Other)
Overall Status
Terminated
CT.gov ID
NCT01875770
Collaborator
(none)
47
1
98
0.5

Study Details

Study Description

Brief Summary

This research is being done to assess the long term prognosis of patients treated with ranibizumab for edema due to retinal vein occlusion.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    People treated with ranibizumab for edema due to retinal vein occlusion as part of previous studies at the Wilmer Eye Institute and who are currently being seen by their ophthalmologist at the Wilmer Eye Institute are followed up to assess long term outcomes

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    47 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Continuing Assessment of Patients Treated With ranibizUmab for REtinal Vein Occlusion (CAPTURE)
    Actual Study Start Date :
    Jan 1, 2013
    Actual Primary Completion Date :
    Oct 11, 2018
    Actual Study Completion Date :
    Mar 3, 2021

    Arms and Interventions

    Arm Intervention/Treatment
    Treated with Ranibizumab in previous trial

    Treated with Ranibizumab in previous trial

    Outcome Measures

    Primary Outcome Measures

    1. Mean change from baseline in BCVA at 5 and 10 years. [10 years]

      Mean change from baseline in BCVA at 5 and 10 years.

    Secondary Outcome Measures

    1. Mean change from baseline in foveal thickness at 5 and 10 years [10 years]

      Mean change from baseline in foveal thickness at 5 and 10 years

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 99 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • All patients who have been enrolled in the following three trials will be included in the study:
    1. "A Pilot, Open-Label Study of the Safety, Tolerability, and Bioactivity of Multiple Intravitreal Injections of Ranibizumab in Subjects with Macular Edema Secondary to Vein Occlusions.", B) "Extended follow-up of patients with macular edema due to bRanch rETinal vein occlusion (BRVO) or centrAl retinal veIn occlusioN (CRVO) previously treated with intravitreal ranibizumab (RETAIN) " C) "RanibizumabDosE Comparison (0.5mg and 2.0mg) and the Role of LAser in the ManagemenT of REtinal Vein Occlusion - A Pharmacodynamic Approach (RELATE)"
    Exclusion Criteria:
    • None

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Wilmer Eye Institute Baltimore Maryland United States 21287

    Sponsors and Collaborators

    • Johns Hopkins University

    Investigators

    • Principal Investigator: Peter Campochiaro, MD, Johns Hopkins University

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Johns Hopkins University
    ClinicalTrials.gov Identifier:
    NCT01875770
    Other Study ID Numbers:
    • NA_00079952
    First Posted:
    Jun 12, 2013
    Last Update Posted:
    Oct 12, 2021
    Last Verified:
    May 1, 2021
    Keywords provided by Johns Hopkins University
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Oct 12, 2021